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Introduction
The Hiper-IgD Syndrome (HIDS) is an autoinflammatory
disease characterized by recurrent febrile episodes each 4–
8 weeks accompanied by an intense inflammatory reac-
tion, lymphadenopathy, abdominal pain, diarrhea,
arthralgias, hepatosplenomegaly and cutaneous signs [1].
Mutations in the gene that codifies the enzyme meval-
onate kinase (MVK), located in the chromosome 12q24,
have been demonstrated to be the cause of this syndrome
[2].
Objective
We describe the clinical and genetic findings of three fam-
ilies (five patients) with diagnosis of HIDS and confirmed
mutational analysis.
Methods
We present a retrospective analysis of the patients and its
genealogical tree. The mutational analysis was made by
the service of Inmunology of the Hospital Clínic of Barce-
lona.
Results
Clinically the five patients presented the typical symp-
tomatology with recurrent febrile episodes, intense
abdominal pain (a case required several exploratory
laparotomies), cervical lymphadenopathy, diarrhea and
hepatosplenomegaly. One of the patients presented a chi-
lotorax that resolved after discarding amiloidosis and ini-
tiating treatment. In all cases mutations I268T or V377I
were detected. In two of the families, the parents demon-
strated to be heterozygote carriers of one of the two found
mutations.
All the patients have required steroids to high doses, nev-
ertheless, three of the cases have developed steroid
dependency with necessity of biological treatment with
Anakinra, a recombinant, nonglycosylated synthetic form
of the human interleukin-1 receptor antagonist (IL-1Ra),
Kineret®) that in last publications has demonstrated to be
the election treatment since the Hiper IgD Syndrome is
part of the autoinflammatory diseases in whose common
pathogenic mechanism the IL-1 takes part.
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